The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: My first question is on CEQUA. We've heard commentary from one of our peers in the dry eye market about changing their promotion strategy.
What is our view on how we approach the product given the peer mentioned that it is more like a consumer product?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: That's right, sir.
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Yes, sir. Is that a similar strategy...
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: But do we plan a DTC campaign for CEQUA at this point or we haven't decided on that?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Okay. Understood. Sir, currently -- I know it's a very short time frame...
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Understood. Sir, second, I know it's a very short time frame, but the patients that you're seeing coming -- or the likelihood of patients that you'll
see coming on CEQUA, would these be patients which are there on existing treatment or do you see probably new patient coming in? Or there is
a large patient pool, which does not take any prescription product for dry eye? Would that be the target?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Okay. Understood. And one more question, if I may. On the R&D trajectory, given we are tracking much below the 8% to 9%, is it fair to assume
that next year's guidance would be -- I mean, you said higher than FY '20, but closer to 8% and 9%? And would all of the incremental be for ILUMYA?
Or are there any other products that would be included in this incremental amount?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: And would all of the incremental spend be for ILUMYA, sir, or new indications on ILUMYA? Or I think we mentioned 1 more product going to trial
next year.
| 
